Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
09/2003
09/23/2003US6623475 Blood pump without bearing
09/23/2003CA2285005C Sequential release throat drops for relief of cough and cold
09/23/2003CA2271560C Pharmaceutical dosage form for colonic delivery
09/23/2003CA2268927C Aqueous-based pharmaceutical composition
09/23/2003CA2139781C Ophthalmic topical composition containing (s)-timolol hemihydrate
09/23/2003CA2131366C Self-assembling diketopiperazine drug delivery system
09/23/2003CA2100295C A psyllium-hydrocolloid gum composition
09/23/2003CA2072116C Shaped articles as obtained from a thermoplastic starch melt
09/18/2003WO2003076594A2 Genomic screen for epigenetically silenced tumor suppressor genes
09/18/2003WO2003076475A1 Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring
09/18/2003WO2003076455A2 Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein
09/18/2003WO2003076391A2 Urokinase inhibitors, production and use thereof
09/18/2003WO2003075982A1 Multiple compartment bag assembly for dialysis fluid
09/18/2003WO2003075977A2 Agglomerated particles for aerosol drug delivery
09/18/2003WO2003075928A2 Stable pharmaceutical compositions
09/18/2003WO2003075921A2 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
09/18/2003WO2003075920A1 Eye drops containing tetrazole derivative
09/18/2003WO2003075919A1 Tablet containing pilsicainide hydrochloride (dry)
09/18/2003WO2003075918A1 Tablet containing pilsicainide hydrochloride (wet)
09/18/2003WO2003075909A1 Ibuprofen solution for hard shell capsules
09/18/2003WO2003075908A1 Use of adapalene for the treatment of dermatological disorders
09/18/2003WO2003075898A2 Film coatings with controlled release and high stability
09/18/2003WO2003075897A1 Therapeutic system for the controlled release of active ingredients
09/18/2003WO2003075896A1 Coated pharmaceutical single-unit delayed-release forms, based on polyvinyl acetate
09/18/2003WO2003075895A1 Tasted masked veterinary solid compositions
09/18/2003WO2003075894A1 A system for the controlled release of active ingredients
09/18/2003WO2003075893A1 Controlled release dosage forms
09/18/2003WO2003075892A1 Pharmaceutical microparticles
09/18/2003WO2003075891A1 Dispersed solid-containing complex carbohydrate
09/18/2003WO2003075890A1 Methods for entrapment of bioactive agent in a liposome or lipid complex
09/18/2003WO2003075889A1 An inhalation system for prevention and treatment of intracellular infections
09/18/2003WO2003075888A2 Materials containing multiple layers of vesicles
09/18/2003WO2003075887A1 Sustained release drug formulations containing a carrier peptide
09/18/2003WO2003075885A1 Composition having gelling properties for the prolonged delivery of bioactive substances
09/18/2003WO2003075884A1 Effervescent compositions comprising bisphosphonates and methods related thereto
09/18/2003WO2003075861A1 Antioxidative preparations
09/18/2003WO2003075852A2 Antibiotic composition
09/18/2003WO2003075842A2 Stable formulations of angiotensin converting enzyme (ace) inhibitors
09/18/2003WO2003075839A2 Methods of inducing terminal differentiation
09/18/2003WO2003075834A2 Activated protein c formulations
09/18/2003WO2003075830A2 Oral controlled drug delivery system containing carbamazepine
09/18/2003WO2003075829A2 Tasteless directly compressible fast-dissolving complexes and pharmaceutical formulations thereof
09/18/2003WO2003075812A1 Controlled delivery patch of active ingredient
09/18/2003WO2003075788A2 Biodegradable microbicidal vaginal barrier device
09/18/2003WO2003075676A1 Probiotic delivery system
09/18/2003WO2003075661A1 Oral formulations containing nucleotides that inhibit perception of unpleasant taste
09/18/2003WO2003059296A3 Compositions comprising collagen and metalloprotease inhibitors
09/18/2003WO2003047557A3 Device and patch for controlling the release of vanillin
09/18/2003WO2003047521A3 Composition and method for treatment of otitis media
09/18/2003WO2003045484A3 Open-celled substrates for drug delivery
09/18/2003WO2003043517A3 Dentifrice compositions
09/18/2003WO2003041682A3 Lipid carrier compositions and methods for improved drug retention
09/18/2003WO2003041681A3 Lipid carrier compositions with enhanced blood stability
09/18/2003WO2003039595A3 Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
09/18/2003WO2003032928A3 Therapeutic composition and use
09/18/2003WO2003028600B1 Wipe formulation
09/18/2003WO2003005941A3 Insert for the treatment of dry eye
09/18/2003WO2002083700B1 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
09/18/2003WO2002036110A9 Oral self-emulsifying formulations of pyranone protease inhibitors
09/18/2003US20030176933 Microprocessor controlled ambulatory medical apparatus with hand held communication device
09/18/2003US20030176882 Great saphenous vein varix treatment tool
09/18/2003US20030176854 Implantable drug delivery system
09/18/2003US20030176853 Sustained release delivery systems for solutes
09/18/2003US20030176852 Low profile pivoting joint infusion assembly
09/18/2003US20030176836 Transdermal delivery
09/18/2003US20030176641 Synthetic ion channels
09/18/2003US20030176514 Method for preparing a mixture that can be granulated and carnitine-magnesium hydroxycitrate
09/18/2003US20030176502 Pravastatin pharmaceutical formulations and methods of their use
09/18/2003US20030176501 For use in inhibiting HMG-CoA reductase; therapy and prophylaxis of hypercholesterolemia, atherosclerotic disease
09/18/2003US20030176472 Method of tizanidine therapy
09/18/2003US20030176467 Nicotine compositions
09/18/2003US20030176463 For therapy of disease states resulting from angiogenesis; can be administered orally
09/18/2003US20030176452 Oral absorption
09/18/2003US20030176420 Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists
09/18/2003US20030176408 For topical application, penetration
09/18/2003US20030176406 Polycaprolactone-b-poly (ethylene oxide) copolymer non-cross-linked micelles as a delivery vehicle for steroid
09/18/2003US20030176399 Pharmaceutical formulations comprising indolinone derivatives
09/18/2003US20030176391 Oral fludara of high-purity formulation with quick release of active ingredient
09/18/2003US20030176379 Useful in the administration of a drug, therapy
09/18/2003US20030176369 Stabilized azithromycin compositions
09/18/2003US20030176359 Administration of a thiol-based chemoprotectant compound
09/18/2003US20030176353 Lys-pro-val dimer, formulations and applications
09/18/2003US20030176345 Wound healing composition and method for use thereof
09/18/2003US20030175876 a neurotrophin with biological activity on the central/peripheral nervous system cells; used for treating GDNF-responsive conditions such as alzhiemer's, parkinsons; device for nerve damage treatment
09/18/2003US20030175849 Identifying compounds for treating vision defects associated with intraocular pressure
09/18/2003US20030175517 Production of polyelectrolyte capsules by surface precipitation
09/18/2003US20030175396 Sugar-free products with improved characteristics
09/18/2003US20030175370 Dry mixture of carbohydrates and drugs; wound healing agents
09/18/2003US20030175366 Plant Extracts and Methods of Treating Skin Therewith
09/18/2003US20030175357 Prolonged anesthesia in joints and body spaces
09/18/2003US20030175356 Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma
09/18/2003US20030175355 Fast melt multiparticulate formulations for oral delivery
09/18/2003US20030175354 Antiemetic, anti-motion sustained release drug delivery system
09/18/2003US20030175353 Comprises carbamazepine and one or more hydrophobic polymers in homogenous admixture, wherein system does not comprise means capable of preventing conversion of carbamazepine to its dihydrate form
09/18/2003US20030175352 Having a plurality of solid, polymeric matrix beads comprising considerable amounts of greasy/oily/sticky substances and having fast release characteristics; drug delivery
09/18/2003US20030175351 Pharmaceutical composition for oral use with improved absorption
09/18/2003US20030175350 Containing thyrotropin-releasing hormone or derivatives thereof as medicinally active ingredient; excellent in absorbability
09/18/2003US20030175349 Core surrounded by release rate controlling membrane, core consisting of therapeutically active moiety having limited water solubility, alkalinizing agent or buffer, osmotically effective solute, semipermeable and permeable membranes
09/18/2003US20030175348 Novel pharmaceutical formulation with controlled release of active substances
09/18/2003US20030175347 Durable film coating compositions having sustained slow-release capability, and methods of use therefor
1 ... 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 ... 2991